ATAI (atai.life) Enterprise Value-to-Revenue Coefficient

Official company branding of atai Life Sciences (ATAI)

The EV/Revenue ratio for Atai Life Sciences N.V. (ATAI) on GURU.Markets displays 559740.49, which represents the current level of the metric. The psychedelics sector is associated with immense risks and a fierce struggle for drug approvals. Atai Life Sciences N.V. (ATAI) employs an M&A strategy to consolidate scientific laboratories, although the R&D stage temporarily increases clinical trial costs.

ATAI Atai Life Sciences N.V. EV/Sales Multiple (11/23/2025 - 09/26/2026)

ATAI (atai Life Sciences Corp): analytical breakdowns and indicator data

- current quotes and average value forecast:
- business market valuation indicators:
- cash balance and cash flow data:
Fundamental company valuation:ATAI (Atai Life Sciences N.V.)
Product sample of atai Life Sciences NV

The Atai Life Sciences N.V. (ATAI) ecosystem is transforming depression therapy through the synthesis of psychedelics and digital technologies. This innovation is reflected in the company's EV/Sales ratio, which compares the total enterprise value to its revenue, excluding the impact of debt obligations. This metric determines the market premium paid for every dollar of sales. An increase in this indicator signals inflated investor expectations. By analyzing this chart, one can filter out the noise and assess the real value of the assets.